Safety and tolerability in terms of AE and SAE (including death), as recorded in safety measures. From baseline until 28 days after discontinuation of study treatment. [clinicaltrials_resource:10251a4b4c602f82fdc420ae4525f6a9]
Safety measures include AEs, SAEs, ECG, physical examination, pulse, blood pressure, body temperature, weight and laboratory variables
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Safety and tolerability in terms of AE and SAE (including death), as recorded in safety measures. From baseline until 28 days after discontinuation of study treatment. [clinicaltrials_resource:10251a4b4c602f82fdc420ae4525f6a9]
Safety measures include AEs, SAEs, ECG, physical examination, pulse, blood pressure, body temperature, weight and laboratory variables
Bio2RDF identifier
10251a4b4c602f82fdc420ae4525f6a9
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:10251a4b4c602f82fdc420ae4525f6a9
measure [clinicaltrials_vocabulary:measure]
Safety and tolerability in ter ...... s recorded in safety measures.
time frame [clinicaltrials_vocabulary:time-frame]
From baseline until 28 days after discontinuation of study treatment.
description
Safety measures include AEs, S ...... eight and laboratory variables
identifier
clinicaltrials_resource:10251a4b4c602f82fdc420ae4525f6a9
title
Safety and tolerability in ter ...... ntinuation of study treatment.
@en
type
label
Safety and tolerability in ter ...... 51a4b4c602f82fdc420ae4525f6a9]
@en